Literature DB >> 30537741

Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection.

Shi-Fang Li1,2, Mei-Jiao Gong1,3, Fu-Rong Zhao1,2, Jun-Jun Shao1,2, Yin-Li Xie1,2, Yong-Guang Zhang1,2, Hui-Yun Chang4,5.   

Abstract

The interferons (IFNs) are a primary defense against pathogens because of the strong antiviral activities they induce. IFNs can be classified into three groups: type I, type II and type III, according to their genetic, structural, and functional characteristics and their receptors on the cell surface. The type I IFNs are the largest group and include IFN-α, IFN-β, IFN-ε, IFN-ω, IFN-κ, IFN-δ, IFN-τ and IFN-ζ. The use of IFNs for the treatment of viral infectious diseases on their antiviral activity may become an important therapeutic option, for example, IFN-α is well known for the successful treatment of hepatitis B and C virus infections, and interest is increasing in the antiviral efficacy of other novel IFN classes and their potential applications. Therefore, in this review, we summarize the recent progress in the study of the biological activities of all the type I IFN classes and their potential applications in the treatment of infections with immunodeficiency virus, hepatitis viruses, and influenza viruses.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Antiviral; Hepatitis; Immunodeficiency virus; Influenza Virus; Type I IFN classes; Viral infection

Mesh:

Substances:

Year:  2018        PMID: 30537741     DOI: 10.1159/000495897

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  47 in total

Review 1.  Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference.

Authors:  John H Beigel; Hannah H Nam; Peter L Adams; Amy Krafft; William L Ince; Samer S El-Kamary; Amy C Sims
Journal:  Antiviral Res       Date:  2019-04-08       Impact factor: 5.970

Review 2.  Immunoregulatory therapy strategies that target cytokine storms in patients with COVID-19 (Review).

Authors:  Xianyao Wang; Zhixu He; Xing Zhao
Journal:  Exp Ther Med       Date:  2021-02-03       Impact factor: 2.447

Review 3.  Type I Interferons in Autoimmunity.

Authors:  Ruth Fernandez-Ruiz; Timothy B Niewold
Journal:  J Invest Dermatol       Date:  2022-01-10       Impact factor: 8.551

4.  Type I IFN Sensing by cDCs and CD4+ T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8+ T Cells.

Authors:  Jamie L Shirley; Geoffrey D Keeler; Alexandra Sherman; Irene Zolotukhin; David M Markusic; Brad E Hoffman; Laurence M Morel; Mark A Wallet; Cox Terhorst; Roland W Herzog
Journal:  Mol Ther       Date:  2019-11-15       Impact factor: 11.454

5.  Aminopeptidase N Expression, Not Interferon Responses, Determines the Intestinal Segmental Tropism of Porcine Deltacoronavirus.

Authors:  Lingdan Yin; Jianfei Chen; Liang Li; Shanshan Guo; Mei Xue; Jialin Zhang; Xiang Liu; Li Feng; Pinghuang Liu
Journal:  J Virol       Date:  2020-07-01       Impact factor: 5.103

6.  Organoid modeling of Zika and herpes simplex virus 1 infections reveals virus-specific responses leading to microcephaly.

Authors:  Veronica Krenn; Camilla Bosone; Thomas R Burkard; Julia Spanier; Ulrich Kalinke; Arianna Calistri; Cristiano Salata; Raissa Rilo Christoff; Patricia Pestana Garcez; Ali Mirazimi; Jürgen A Knoblich
Journal:  Cell Stem Cell       Date:  2021-04-09       Impact factor: 25.269

7.  Antimicrobial Peptide Omiganan Enhances Interferon Responses to Endosomal Toll-Like Receptor Ligands in Human Peripheral Blood Mononuclear Cells.

Authors:  Hendrika W Grievink; Silvana M G Jirka; Tess D Woutman; Mascha Schoonakker; Robert Rissmann; Karen E Malone; Gary Feiss; Matthijs Moerland
Journal:  Clin Transl Sci       Date:  2020-04-21       Impact factor: 4.689

Review 8.  Crosstalk between Interleukin-1β and Type I Interferons Signaling in Autoinflammatory Diseases.

Authors:  Philippe Georgel
Journal:  Cells       Date:  2021-05-08       Impact factor: 6.600

9.  Interplay between hypoxia and inflammation contributes to the progression and severity of respiratory viral diseases.

Authors:  Sulagna Bhattacharya; Sakshi Agarwal; Nishith M Shrimali; Prasenjit Guchhait
Journal:  Mol Aspects Med       Date:  2021-07-19

Review 10.  Abnormalities of the type I interferon signaling pathway in lupus autoimmunity.

Authors:  Stefania Gallucci; Sowmya Meka; Ana M Gamero
Journal:  Cytokine       Date:  2021-07-30       Impact factor: 3.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.